MedInCell Stock Tests Key Technical Threshold Despite +60% Yearly Gain
MedInCell falls by 2.48% to 23.60 euros this Friday, amidst a significant retreat in European markets. The Montpellier-based biotech stock, still showing an increase of over 60% over the year, is however undergoing a correction of nearly 20% over three months.
During the session, MedInCell's stock price is at 23.60 euros, above its 50-day moving average (22.94 euros) but slightly below its 200-day moving average (23.99 euros). This positioning reflects a consolidation phase after the rebound observed in recent weeks: the stock, which had reached levels close to the support at 20.24 euros, has recovered but has not yet consistently broken through its identified resistance at 25.12 euros. The RSI, at 57, is in a neutral zone, indicating neither an overbought nor oversold condition. Within the Bollinger Bands, the price moves in the upper half of the channel, at 58% of the band, far from the upper limit at 25.39 euros and comfortably above the lower limit at 21.14 euros. Thus, the stock does not show any particular technical tension signal, but today's loss of 2.48% brings it closer to its 200-day moving average, a breach of which could open up a more pronounced downward space.
Upcoming Catalysts and Market Context
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The next identified catalyst for MedInCell is the publication of its annual results for the fiscal year 2025-2026, scheduled for June 16th. This date will be crucial to assess the operational trajectory of the company specializing in extended-release drug technologies. The general assembly is scheduled for September 10th. Today's market context does not favor growth stocks. The CAC 40 is down 1.05% during the session, while the SBF 120 loses 1% at the same time. In the European pharmaceutical sector, peers also show negative performances: Sanofi is down by 0.77% and UCB loses 2.23%. Across the Atlantic, Eli Lilly ended the day down by 0.42%, while Johnson & Johnson advanced by 2.01%. MedInCell's negative beta, at -0.53, historically suggests a market-decorrelated behavior, making today's drop all the more notable in a context where the entire sector is trending downward.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
